Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6489299B2 · kind B2 · utility
3Cited by
2References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 19, 2001 |
| Grant date | Dec 3, 2002 |
| Priority date | — |
| Expiry date | Nov 19, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.